Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.
Sign Up to like & getrecommendations! Published in 2021 at "Thoracic cancer"
DOI: 10.1111/1759-7714.14156
Abstract: BACKGROUND Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have improved the prognosis of mutant lung cancer; however, the clinical application value of TKIs for nonclassical EGFR mutation is unclear, especially for patients with… read more here.
Keywords: response; treatment; uncommon mutations; rare uncommon ... See more keywords